The detection of serum autoantibodies to IGF2BP1 in esophageal squamous cell carcinoma [94] and IGF2BP1/3 in colon cancer [95] contributes to identifying patients with cancer, and when combined with other TAAs, achieves greater sensitivity and specificity for diagnosis. Here, IGF2BP1 is linked to cancer.